Treatment of malignant ascites and pleurisy by a streptococcal preparation OK-432 with fresh frozen plasma--a mechanism of polymorphonuclear leukocyte (PMN) accumulation

Int J Immunopharmacol. 1989;11(2):117-28. doi: 10.1016/0192-0561(89)90063-5.

Abstract

A single injection of a streptococcal preparation, OK-432, with fresh frozen plasma (FFP) (or fresh human serum) into the peritoneal or pleural cavity for the treatment of malignant ascites or pleurisy resulted in a complete reduction of ascitic fluid or pleural effusion in 5 out of 11 patients. FFP was used a further source of complement for the effective accumulation of antitumor polymorphonuclear leukocytes (PMNs) by complement-derived chemotactic factors in the cavity. C5a increased in the fluids 3-9 h after the injection and preceded a massive increase in PMNs. C1 inhibitor (C1INH) and C3b inactivator (C3bINA) decreased in several cases 6 h after the treatment. Chemotactic arachidonic acid metabolites, thromboxane B2(TXB2) as a characteristics of TXA2, and leukotriene B4(LTB4) also increased at the same time even in cases where C5a changed only minimally, and may play a role in accumulating antitumor PMNs in the cavity.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Ascites / immunology
  • Ascites / therapy*
  • Biological Products / therapeutic use*
  • Complement Activation
  • Complement C5 / analysis
  • Complement C5a
  • Female
  • Freezing
  • Humans
  • Immunization, Passive*
  • Leukotriene B4 / analysis
  • Male
  • Middle Aged
  • Neoplasms / therapy*
  • Neutrophils / immunology*
  • Picibanil / adverse effects
  • Picibanil / therapeutic use*
  • Pleurisy / immunology
  • Pleurisy / therapy*
  • Thromboxane B2 / analysis

Substances

  • Biological Products
  • Complement C5
  • Leukotriene B4
  • Picibanil
  • Thromboxane B2
  • Complement C5a